These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1628965)

  • 21. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
    Martínez-Cabot A; Messeguer A
    Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Epidemic due to the ingestion of adulterated, toxic cooking oil: a new type of sclerodermatous syndrome].
    Olmedo Garzón FJ; Zea Mendoza AC; Alonso Ruiz A; Salazar Vallinas JM; García Villanueva M; Rocamora Ripoll A; Beltrán Gutiérrez J
    Med Clin (Barc); 1982 Jun; 79(1):1-8. PubMed ID: 7121102
    [No Abstract]   [Full Text] [Related]  

  • 23. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report.
    Philen RM; Posada M
    Semin Arthritis Rheum; 1993 Oct; 23(2):104-24. PubMed ID: 8266108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3-(Phenylamino)alanine--a link between eosinophilia-myalgia syndrome and toxic oil syndrome?
    Philen RM; Hill RH
    Mayo Clin Proc; 1993 Feb; 68(2):197-200. PubMed ID: 8423703
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunohistochemical analysis of lymphocytes in postmortem study of the heart from fatal cases of the eosinophilia myalgia syndrome and of the toxic oil syndrome.
    Hayashi T; James TN
    Am Heart J; 1994 May; 127(5):1298-308. PubMed ID: 8172059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels.
    Hertzman PA
    Adv Exp Med Biol; 1996; 398():339-42. PubMed ID: 8906286
    [No Abstract]   [Full Text] [Related]  

  • 27. Genetic approaches in the understanding of Toxic Oil Syndrome.
    Cárdaba B; del Pozo V; Gallardo S; Palomino P; Posada M; Lahoz C
    Toxicol Lett; 2006 Feb; 161(1):83-8. PubMed ID: 16236472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic oil syndrome: survival in the whole cohort between 1981 and 1995.
    Sánchez-Porro Valadés P; Posada de la Paz M; de Andrés Copa P; Gimenez Ribota O; Abaitua Borda I
    J Clin Epidemiol; 2003 Jul; 56(7):701-8. PubMed ID: 12921940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The toxic oil syndrome: an example of an exogenously induced autoimmune reaction. Toxic oil syndrome.
    Bell SA
    Mol Biol Rep; 1996; 23(3-4):261-3. PubMed ID: 9112238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic oil syndrome: the perspective after 20 years.
    Posada de la Paz M; Philen RM; Borda AI
    Epidemiol Rev; 2001; 23(2):231-47. PubMed ID: 12192735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome.
    Kilbourne EM; Posada de la Paz M; Abaitua Borda I; Diez Ruiz-Navarro M; Philen RM; Falk H
    J Am Coll Cardiol; 1991 Sep; 18(3):711-7. PubMed ID: 1869734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrogenic growth factors in the eosinophilia-myalgia syndrome and the toxic oil syndrome.
    Kaufman LD; Gruber BL; Gomez-Reino JJ; Miller F
    Arch Dermatol; 1994 Jan; 130(1):41-7. PubMed ID: 8285738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxic oil syndrome and eosinophilia myalgia syndrome: similar, different or the same disorder?
    Kaufman LD; Izquierdo Martinez M; Gomez-Reino JJ
    J Rheumatol; 1994 Dec; 21(12):2177-8. PubMed ID: 7699614
    [No Abstract]   [Full Text] [Related]  

  • 34. Short-term adverse effects in humans of ingested mineral oils, their additives and possible contaminants--a review.
    Hard GC
    Hum Exp Toxicol; 2000 Mar; 19(3):158-72. PubMed ID: 10889514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The toxic oil syndrome and the eosinophilia-myalgia syndrome: pursuing clinical parallels.
    Hertzman PA; Borda IA
    J Rheumatol; 1993 Oct; 20(10):1707-10. PubMed ID: 8295182
    [No Abstract]   [Full Text] [Related]  

  • 36. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome.
    Arnaiz-Villena A; Martinez-Laso J; Corell A; Allende L; Rosal M; Gomez-Reino JJ; Vicario JL
    Eur J Immunogenet; 1996 Jun; 23(3):211-9. PubMed ID: 8803534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of eosinophilia myalgia syndrome and related disorders.
    Clauw DJ
    Adv Exp Med Biol; 1996; 398():331-8. PubMed ID: 8906285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Skin manifestations of toxic syndrome due to denatured rapeseed oil].
    Fonseca E
    Actas Dermosifiliogr; 2009 Dec; 100(10):857-60. PubMed ID: 20038361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late cases of toxic oil syndrome: evidence that the aetiological agent persisted in oil stored for up to one year.
    Posada de la Paz M; Abaitua Borda I; Kilbourne EM; Tabuenca Oliver JM; Diaz de Rojas F; Castro Garcia M
    Food Chem Toxicol; 1989 Aug; 27(8):517-21. PubMed ID: 2792975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary hypertension in patients with eosinophilia-myalgia syndrome or toxic oil syndrome.
    Cheng TO
    Mayo Clin Proc; 1993 Aug; 68(8):823-4. PubMed ID: 8331987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.